Nathalie Dubois-Stringfellow - Oct 22, 2025 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: SVP-CHIEF DEVELOPMENT OFFICER
Signature: /s/ Scott Willoughby, Attorney-in-Fact
Stock symbol: SGMO
Transactions as of: Oct 22, 2025
Transactions value $: -$28,869
Form type: 4
Date filed: 10/24/2025, 05:00 PM
Previous filing: Aug 26, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dubois-Stringfellow Nathalie	SVP-CHIEF DEVELOPMENT OFFICER	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND	/s/ Scott Willoughby, Attorney-in-Fact	2025-10-24	0001947007

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGMO	Common Stock	Tax liability	-$28.9K	-43.7K	-5.71%	$0.66	722K	Oct 22, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2	Includes: (a) 45,321 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Content

Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Includes: (a) 45,321 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.